2025-12-23 - Analysis Report
Okay, here's a comprehensive report on Tempus AI (TEM), summarizing the provided data:

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Tempus AI Inc. is focused on personalized medicine through data and artificial intelligence.
*   **TEM Cumulative Return:** 15.06%
*   **VOO Cumulative Return:** 30.11%
*   **Divergence:** -15.0 (Current divergence from VOO)
*   **Relative Divergence:** 22.3 (This places the current divergence relatively low compared to its historical range).

**Analysis:** TEM has significantly underperformed the S&P 500. The relative divergence suggests the stock is currently experiencing relatively large underperformance within its historical range against VOO.

**Alpha, Beta Analysis:**

|            | CAGR   | MDD    | Alpha   | Beta | Cap(B) |
|------------|--------|--------|---------|------|--------|
| 2023-2025  | 15.0%  | 76.7%  | -14.0%  | 0.3  | 11.7   |

*   **CAGR:** A 15.0% Compound Annual Growth Rate is decent, but needs to be interpreted relative to the risks.
*   **MDD:** A 76.7% Maximum Drawdown (MDD) indicates substantial risk and volatility.
*   **Alpha:** -14.0% Alpha suggests TEM has underperformed relative to its risk (Beta) adjusted benchmark.
*   **Beta:** A Beta of 0.3 suggests that TEM is less volatile than the market.
*   **Cap:** $11.7 Billion Market Capitalization

**Analysis:** The table confirms the underperformance discussed above, showing that the stock price is significantly less volatile to market changes (Beta = 0.3) with very high risk (MDD = 76.7%).

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 64.46
*   **Last Market Data:** Price = 65.92, Previous Close = 64.46, Change = 2.26
*   **5-day SMA:** 65.61
*   **20-day SMA:** 72.86
*   **60-day SMA:** 80.13

**Analysis:** The stock price is below all three moving averages, suggesting a short-term downtrend. The recent price increase indicated by the last market data may indicate a potential rebound, though it's still early to confirm.

**3. Indicators Analysis**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 23.89 (Oversold)
*   **PPO (Percentage Price Oscillator):** -1.42
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (14 shares - Very Safe - MRI:0.90) Monthly invest 5.0% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -9.7 (Negative - Short-term decline)
*   **Last Market Data Fluctuation:** {'price': 65.92, 'previousClose': 64.46, 'change': 2.26}
*   **Expected Return (%):** NaN

**Analysis:**
*   The MRI suggests a medium investment risk.
*   The RSI indicates that the stock is currently oversold and a potential reversal is possible.
*   PPO is negative, confirming the downtrend, but also showing a convergence in the short-term that may reverse this.
*   The recent relative divergence change indicates a continued short-term decline.
*   The recent fluctuation is up, which can potentially lead to a reverse on the trend.
*   The "Expected Return" is NaN which is not great for investment, it may not be a good long term investment.

**4. Recent News & Significant Events**

*   **Analyst Price Targets:** Several analysts have lowered their price targets for TEM to $80, maintaining a Neutral rating.
*   **Transition Period:** The company is in a "pivotal transition," as noted by Yahoo Finance.
*   **Path to Profitability:** Despite GAAP losses, Tempus AI is approaching profitability.
*   **AI Stock Potential:** Some articles suggest Tempus AI could be a significant AI stock to buy.

**5. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 2.14 (Approaching Buy)
*   **Number of Opinions:** 12
*   **Target Price (Avg/High/Low):** 88.92 / 105.00 / 80.00
*   **Recent Rating Changes:** Not specified.

**5. Comprehensive Analysis (Summary)**

Tempus AI (TEM) is a company with significant potential in the personalized medicine and AI space, but the data suggests caution.

*   **Underperformance:** The stock has significantly underperformed the S&P 500, as noted by the negative divergence and Alpha.
*   **Volatility:** High MDD (76.7%) reflects the risk associated with the stock.
*   **Downtrend:** The stock price is below its moving averages, and the relative divergence change indicates a short-term downtrend.
*   **Oversold:** The RSI indicates the stock may be oversold, and a potential short-term rebound.
*   **Analyst Sentiment:** Analyst sentiment remains moderately positive with a "Buy" consensus, despite recent price target reductions to $80. The average price target remains higher.
*   **News is Mixed:** The news suggests both a potential for growth and a period of transition. The company's path to profitability is promising, but the recent price target reductions and the transitional period should be considered.

**Overall Recommendation:**

Based on the data, TEM currently appears to be a high-risk, potentially high-reward investment. The negative divergence and downtrend suggest caution in the short-term. However, the oversold RSI, potential for rebound, positive analyst sentiment, and the company's long-term prospects in AI and personalized medicine warrant a closer look. Investors should carefully weigh the risks and consider if TEM aligns with their investment goals and risk tolerance.

**Disclaimer:** This analysis is based on the provided data and should not be considered financial advice. Conduct thorough research and consult with a financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.